Physician profile
Todd Morrow
NPI 1063418549
$2,095.92
in general payments reported to CMS, 2019-2025
14 companies · $420 in 2025
The $420 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.03 · 2020: $55.98 · 2021: $341 · 2022: $409 · 2023: $566 · 2024: $251 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.41 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $630.54 | 2020-2025 | |
| Glaxosmithkline, LLC. | $529.49 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $352.88 | 2020-2025 | Dupixent |
| Optinose US, INC. | $311.53 | 2019-2025 | |
| Medtronic, INC. | $45.34 | 2023-2024 | Sinuva |
| Intersect Ent, INC. | $40.42 | 2021 | |
| Aerin Medical INC. | $37.68 | 2024 | |
| Amgen INC. | $34.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.80 | 2025 | Takhzyro |
| Stryker Corporation | $27.34 | 2025 | Xpress Loprofile |
| Merck Sharp & Dohme LLC | $14.48 | 2021 | |
| Blueprint Medicines Corporation | $13.65 | 2024 | Ayvakit |
| Alk-Abello, INC | $12.42 | 2019 | |
| Covis Pharma Gmbh | $12.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.